Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,288.30 +6.39 (+0.50%)

Official Closing Price Updated: 4:10 PM EDT, Oct 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Viking Therapeutics Just Raised $575 Million. Here's What It Means for the Obesity Stock's Next Chapter. ↗

October 18, 2026

Viking Therapeutics raised $575 million to fund major obesity drug trials, develop its pipeline, and support commercial development of any approvals for VK2735.

Via The Motley Fool

Novo Trades at Less Than 12 Times Earnings. Is This the Buying Opportunity of the Decade? ↗

October 18, 2026

Novo is facing some headwinds, but it has a plan to overcome them.

Via The Motley Fool

Ken Griffin Increased His Position in This Dividend King by a Whopping 546% in Q2. Here's Why It's Still a Buy. ↗

October 18, 2026

It was Griffin's biggest add for Citadel last quarter.

Via The Motley Fool

Topics Economy

Cathie Wood Keeps Buying Beam Therapeutics on the Dip. Should You Follow Her Lead? ↗

October 17, 2026

The gene-editing biotech stock is down more than 12% this year.

Via The Motley Fool

Topics ETFs Lawsuit

If a Stock Market Crash Is Coming, History Says These 3 ETFs Are the Smartest Buys ↗

October 17, 2026

These funds can help you weather any storm that might be on the way.

Via The Motley Fool

Topics ETFs Stocks

Forget Zepbound: 3 Newer Drugs That Could Power Eli Lilly's Next Leg Higher ↗

October 16, 2026

Eli Lilly's greatest strength isn't Zepbound. It is the company's drug discovery engine.

Via The Motley Fool

Novo Nordisk and Eli Lilly Just Got Some Fantastic News ↗

October 16, 2026

A new government-funded study found that GLP-1 drugs slow the aging process in mice.

Via The Motley Fool

Eli Lilly's Biggest Shareholder Is Selling $347 Million of Stock. Should You Sell Too? ↗

October 16, 2026

The Lilly Foundation is unloading 300,000 shares of the stock.

Via The Motley Fool

Stock Split Watch: Is Eli Lilly Next? ↗

October 15, 2026

The stock has soared 25% in six months.

Via The Motley Fool

Meet the Low-Cost Vanguard ETF With Taiwan Semiconductor, Samsung Electronics, SK Hynix, and ASML as Its 4 Largest Holdings ↗

October 15, 2026

International stock ETFs offer superior diversification, lower valuations, and higher yields than S&P 500 ETFs like VOO.

Via The Motley Fool

Topics ETFs Stocks

5 Stocks to Start With if You Only Have $1,000 ↗

October 15, 2026

Even if you add nothing at all, $1,000 can accomplish a lot over decades.

Via The Motley Fool

Topics Artificial Intelligence

What Is Market Cap? The Definition Every Investor Needs Before Picking Their First Stock ↗

October 15, 2026

Different categories offer different benefits for investors.

Via The Motley Fool

Topics Artificial Intelligence

Stock Market Today: Hot Inflation and a Neocloud Shakeout Sink the Nasdaq ↗

October 15, 2026

Via Chartmill

Topics Economy

Top S&P500 movers in Wednesday's session ↗

October 14, 2026

Via Chartmill

Stock Market Midday, Oct. 14: Hot Inflation Weighs on Markets, CoreWeave Plummets 15% ↗

October 14, 2026

On Oct. 14, 2026, a hotter-than-expected CPI report pressures growth stocks and the semiconductor selloff continues.

Via The Motley Fool

Topics Artificial Intelligence Bonds Economy

Exploring the top movers within the S&P500 index during today's session. ↗

October 14, 2026

Via Chartmill

Meet the Vanguard ETF That Has Outperformed the Market Nearly 64% of the Time -- and Will Likely Continue Doing So ↗

October 14, 2026

It's banking on winners continuing to run.

Via The Motley Fool

Topics ETFs Stocks

Q2 Earnings Outperformers: Elanco (NYSE:ELAN) And The Rest Of The Pharmaceuticals Stocks

October 13, 2026

Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Kura Oncology Launches $50M-Backed Diabetes Venture for Oral Menin Inhibitor ↗

October 13, 2026

Kura Oncology (NASDAQ:KURA) and its newly formed affiliate Caspian Therapeutics outlined plans to develop KO-7246, an oral menin inhibitor, for diabetes, citing preclinical data that the companies said...

Via MarketBeat

Topics Intellectual Property

Bristol Myers Squibb vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 13, 2026

Bristol Myers Squibb recovered to $7.1B in net income while Eli Lilly more than doubled profits to $20.6B, a stark contrast in momentum that reshapes the value-versus-growth debate.

Via The Motley Fool

3 Dividend Growth Stocks That Have Doubled Their Payouts in 5 Years ↗

October 13, 2026

These stocks have rewarded their shareholders with significant dividend increases in recent years and are likely to continue doing so in the future.

Via The Motley Fool

Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)? ↗

October 13, 2026

FHLC offers broader sector exposure at a 0.08% expense ratio, compared with IBB's concentrated biotech focus at 0.44%, but IBB delivered stronger 1-year returns despite higher volatility.

Via The Motley Fool

Topics ETFs

Eli Lilly Reports Earnings on Oct. 29. Here's Why the Retatrutide Story Matters More Than the Quarter. ↗

October 13, 2026

Eli Lilly's next big growth driver could be bigger than Zepbound.

Via The Motley Fool

Eli Lilly Expects Up to $87 Billion in 2026 Revenue. Here's Why the Stock Still Looks Undervalued. ↗

October 13, 2026

This pharma stock has climbed in the triple digits in recent years.

Via The Motley Fool

Will Eli Lilly Do a Stock Split Before the End of 2026? ↗

October 13, 2026

Eli Lilly's stock price is comfortably above $1,000, and management could easily justify doing a stock split.

Via The Motley Fool

AbbVie vs. Eli Lilly: Which Healthcare Stock Is a Better Buy in 2026? ↗

October 12, 2026

AbbVie trades at a 40% valuation discount but faces revenue concentration risk, while Eli Lilly's cardiometabolic dominance commands a premium.

Via The Motley Fool

4 Healthcare Stocks Worth Owning for the Next Decade ↗

October 12, 2026

Two healthcare stocks that are leading their niches, and two that investors aren't giving enough credit to in the same niches.

Via The Motley Fool

Topics Intellectual Property

Biogen (BIIB) Stock Is Up, What You Need To Know

October 12, 2026

What Happened? Shares of biotech company Biogen (NASDAQ:BIIB) jumped 3.5% in the pre-market session after JPMorgan upgraded the stock to Overweight from Neut...

Via StockStory

Topics Earnings

This Drug Combination for Eli Lilly Generated Significantly More Weight Loss Than Just Zepbound, but Discontinuation Rates Were Also Far Higher. Here's What This Could Mean for the Stock ↗

October 12, 2026

Eli Lilly isn't content with the success of its current GLP-1 drugs; it's on the hunt for even better weight loss solutions.

Via The Motley Fool

Own Both VOO and QQQM? You May Be Buying the Same Stocks Twice. ↗

October 12, 2026

Major index funds are heavily concentrated with the same few tech names. How can investors avoid overlapping stocks?

Via The Motley Fool

Topics ETFs

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.